News

Vynca, a healthcare services and software company that cares for individuals with serious illnesses and complex needs, today ...
AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...
(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy ...
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-a ...
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
On top of being Enhertu’s first foray into DTC marketing, the campaign represents “the first DTC that we’ve developed at Daiichi Sankyo for any of our oncology products," Dan Switzer, head ...
Daiichi Sankyo used the National Cherry Blossom Festival in Washington, D.C. as a platform to raise awareness about its oncology goals.
In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...
Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology, a ...
Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.
Dan Switzer: The cherry trees along the Potomac River are pretty famous, but a little known part of that story is the connection that Daiichi Sankyo has to them. Our company’s history goes all the way ...
TOKYO & BASKING RIDGE, N.J., January 13, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti ...